ReShape Lifesciences (RSLS)

Search documents
ReShape Lifesciences (RSLS) - 2019 Q1 - Earnings Call Transcript
2019-05-20 22:47
ReShape Lifesciences Inc. (NASDAQ:RSLS) Q1 2019 Earnings Conference Call May 20, 2019 4:30 PM ET Company Participants Scott Youngstrom - CFO Bart Bandy - CEO Conference Call Participants Operator Good afternoon and thank you for joining us on today's call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference call is being recorded today, May 20, 2019. I would now like to turn the conference call over to Scott Youngstrom, CFO of ReShape Lifesciences ...
ReShape Lifesciences (RSLS) - 2019 Q1 - Quarterly Report
2019-05-10 21:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37897 OBALON THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1828101 (State of Incorporation) (I.R.S. Employer 5421 Avenida Encinas, S ...
ReShape Lifesciences (RSLS) - 2018 Q4 - Earnings Call Transcript
2019-04-01 23:53
ReShape Lifesciences Inc. (NASDAQ:RSLS) Q4 2018 Results Earnings Conference Call April 1, 2019 4:30 PM ET Company Participants Scott Youngstrom - Chief Financial Officer Dan Gladney - Chairman and CEO Bart Bandy - Chief Executive Officer Conference Call Participants Operator Good afternoon and thank you for joining us on today's call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference call is being recorded today, April 1, 2019. I would now like ...
ReShape Lifesciences (RSLS) - 2018 Q4 - Annual Report
2019-02-22 13:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37897 OBALON THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1828101 (State of Incorporation) (I.R.S. E ...